FDA has approved a new indication for Lilly‘s (NYSE:LLY) Erbitux (cetuximab injection) in combination with Pfizer’s Braftovi (encorafenib) to treat adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation confirmed with an FDA-approved test. The indication covers previously-treated patients. Erbitux is currently the only FDA-approved antibody that targets the epidermal growth factor receptor…
Braftovi Mektovi offers promise for unresectable or metastatic melanoma
Braftovi Mektovi from Array BioPharma won FDA approval in 2018 for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Pfizer acquired Array BioPharma in 2019. Braftovi Mektovi is an example of a BRAF/MEK inhibitor combination. The BRAF gene supports chemical signaling between the cell’s nuclear and the cell’s exterior. The MEK…